O'Kane M J, Lynch P L, Callender M E, Trimble E R
Department of Clinical Biochemistry, The Royal Group of Hospitals, Belfast, UK.
Atherosclerosis. 1997 Jun;131(2):203-10. doi: 10.1016/s0021-9150(97)06108-x.
Patients with primary biliary cirrhosis (PBC) do not appear to have an increased risk of cardiovascular disease despite elevations in serum cholesterol. Recent evidence has pointed to LpA1 (an apo A1 containing particle which contains apo A1 but not apo A2) in protecting against atherosclerosis. The aim of this study was to investigate apo Al containing particles in the serum of patients with PBC. Lipids and apolipoproteins were measured in 31 patients with PBC (30 females) and 27 control subjects (26 females). Patients were divided into 3 groups: group 1 with bilirubin < 18 micromol/l (n = 17); group 2 with bilirubin > 18 micromol/l (n = 11); and group 3 with end stage liver disease (ESLD, n = 3). As expected group 1 and 2 patients had higher total cholesterol, HDL cholesterol and phospholipids than control subjects. Apo B and apo A1 concentrations were similar to control subjects. However, LpA1 was greatly increased: 0.96 g/l (0.60-1.50), median (range) in group 1 and 1.09 g/l (0.75-1.33) in group 2 versus 0.62 g/l (0.45-0.93) for controls both P < 0.005 and the percentage of total apo A1 in the LpA1 fraction was increased: 54.8% (37.9-63.4) in group 1 and 55.7% (47.8-73.7) in group 2 versus 36.8% (25.1-49.1) for controls, both P < 0.005. Apo A2 concentration was reduced in group 1 0.38 g/l (0.30-0.51) and group 2 0.31 g/l (0.14-0.58) versus controls 0.43 g/l (0.36-0.57), P < 0.05 and P < 0.005 respectively. Patients with ESLD had reduced HDL cholesterol, apo A1, LpA1 and apo A2 compared to controls. These results suggest that PBC is associated with an altered distribution of apo A1 favouring an increased concentration of the protective LpA-I particles. Increased LpA1 concentration may be one of the factors contributing to the paradoxically low incidence of atherosclerosis in PBC patients.
原发性胆汁性肝硬化(PBC)患者尽管血清胆固醇升高,但心血管疾病风险似乎并未增加。最近的证据表明,LpA1(一种含载脂蛋白A1的颗粒,含有载脂蛋白A1但不含载脂蛋白A2)具有抗动脉粥样硬化作用。本研究旨在调查PBC患者血清中含载脂蛋白A1的颗粒。对31例PBC患者(30例女性)和27名对照者(26例女性)进行了血脂和载脂蛋白检测。患者分为3组:第1组胆红素<18微摩尔/升(n = 17);第2组胆红素>18微摩尔/升(n = 11);第3组为终末期肝病(ESLD,n = 3)。正如预期的那样,第1组和第2组患者的总胆固醇、高密度脂蛋白胆固醇和磷脂水平高于对照者。载脂蛋白B和载脂蛋白A1浓度与对照者相似。然而,LpA1大幅升高:第1组中位数(范围)为0.96克/升(0.60 - 1.50),第2组为1.09克/升(0.75 - 1.33),而对照组为0.62克/升(0.45 - 0.93),两者P均<0.005,且LpA1组分中总载脂蛋白A1的百分比增加:第1组为54.8%(37.9 - 63.4),第2组为55.7%(47.8 - 73.7),而对照组为36.8%(25.1 - 49.1),两者P均<0.005。第1组载脂蛋白A2浓度降低至0.38克/升(0.30 - 0.51),第2组为0.31克/升(0.14 - 0.58),而对照组为0.43克/升(0.36 - 0.57),P分别<0.05和<0.005。与对照者相比,ESLD患者的高密度脂蛋白胆固醇、载脂蛋白A1、LpA1和载脂蛋白A2均降低。这些结果表明,PBC与载脂蛋白A1分布改变有关,有利于保护型LpA-I颗粒浓度增加。LpA1浓度升高可能是PBC患者动脉粥样硬化发病率反常低的因素之一。